Ragistomig
Based on 1 Customer Validation
Ragistomig can simultaneously target programmed death-ligand 1 (PD-L1) and the 4-1BB receptor. Ragistomig elicits potent anti-tumor T-cell responses without inducing significant toxicity. Ragistomig is applicable for tumor research.
For research use only. We do not sell to patients.
- Purity : 97.469%
- CAS No.: 2763222-58-6
- Molecular Weight:199.524 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized 4-1BB/TNFRSF9 Protein, Human (HEK293, His, HY-P70678) can bind Ragistomig. The EC50 for this effect is 18.03 ng/mL. -
Immobilized PD-L1 Protein, Human (HEK293, HY-P73361) can bind Ragistomig. The EC50 for this effect is 30.13 ng/mL.
Product Details
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
97.469%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
-
Data Sheet (253 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ragistomig
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)